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A B S T R A C T
Background
Several studies have evaluated the clinical effectiveness of endocrine therapy alone in women aged 70 years or over with operable breast
cancer and who are ﬁt for surgery.
Objectives
To systematically review the evidence for the clinical effectiveness of surgery (with or without adjuvant endocrine therapy) in comparison
to primary endocrine therapy in the treatment of operable breast cancer in women aged 70 years and over, both in terms of local
progression and mortality.
Search methods
We conducted an updated search of theCochrane Breast Cancer Group’s SpecialisedRegister (27thMarch 2013) and new searches of the
Cochrane Central Register of Controlled Trials (CENTRAL, 2013, Issue 3), MEDLINE, EMBASE, the World Health Organization’s
International Clinical Trials Registry Platform (apps.who.int/trialsearch/) and www.clinicaltrials.gov, using the search terms ’early breast
cancer’, ’endocrine therapy’, ’psychosocial’ or ’surgery’.
Selection criteria
Randomised trials comparing surgery, with or without adjuvant endocrine therapy, to primary endocrine therapy in the management
of women aged 70 years or over with early breast cancer and who were ﬁt for surgery.
Data collection and analysis
We assessed studies for eligibility and quality, and two review authors independently extracted data from published trials. We derived
hazard ratios for time-to-event outcomes, where possible, and used a ﬁxed-effect model for meta-analysis. We extracted toxicity and
quality-of-life data, where present. Where outcome data were not available, we contacted trialists and requested unpublished data.
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Main results
We identiﬁed seven eligible trials, of which six had published time-to-event data and one was published only in abstract form with no
usable data. The quality of the allocation concealment was adequate in three studies and unclear in the remainder. In each case the
endocrine therapy used was tamoxifen.
Data, based on an estimated 1081 deaths in 1571 women, did not show a statistically signiﬁcant difference in favour of either surgery or
primary endocrine therapy in respect of overall survival. However, there was a statistically signiﬁcant difference in terms of progression-
free survival, which favoured surgery with (474 participants) or without endocrine therapy (164 participants).
The hazard ratios (HRs) for overall survival were: HR 0.98 (95% conﬁdence interval (CI) 0.81 to 1.20, P = 0.85; 3 trials, 495
participants) for surgery alone versus primary endocrine therapy; HR 0.86 (95% CI 0.73 to 1.00, P = 0.06; 3 trials, 1076 participants)
for surgery plus endocrine therapy versus primary endocrine therapy. The HRs for progression-free survival were: HR 0.55 (95% CI
0.39 to 0.77, P = 0.0006) for surgery alone versus primary endocrine therapy; HR 0.65 (95% CI 0.53 to 0.81, P = 0.0001) for surgery
plus endocrine therapy versus primary endocrine therapy (each comparison based on only one trial). Tamoxifen-related adverse effects
included hot ﬂushes, skin rash, vaginal discharge, indigestion, breast pain, sleepiness, headache, vertigo, itching, hair loss, cystitis,
acute thrombophlebitis, nausea, and indigestion. Surgery-related adverse effects included paraesthesia on the ipsilateral arm and lateral
thoracic wall in those who had axillary clearance. One study suggested that those undergoing surgery suffered more psychosocial
morbidity at three months post-surgery, although this difference had disappeared by two years.
Authors’ conclusions
Primary endocrine therapy should only be offered to women with oestrogen receptor (ER)-positive tumours who are unﬁt for surgery,
at increased risk of serious surgical or anaesthetic complications if subjected to surgery, or who refuse surgery. In a cohort of women
with signiﬁcant co-morbid disease and ER-positive tumours it is possible that primary endocrine therapy may be a superior option to
surgery. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as primary therapy for an inﬁrm older population
with ER-positive tumours.
P L A I N L A N G U A G E S U M M A R Y
Surgery versus primary endocrine therapy for elderly women with operable primary breast cancer
While younger women with early-stage, oestrogen-sensitive breast cancer are almost invariably treated with surgery plus endocrine
therapy, (which deprives the cancer of the hormonal stimulus that induces its growth), women over the age of 70 years are frequently
offered endocrine therapy alone. This is known as primary endocrine therapy.
Primary endocrine therapy using tamoxifen (a drug which blocks oestrogen receptors on the cancer cell, inhibiting its growth) was
ﬁrst suggested as a treatment for older women in the 1980s. Tamoxifen was given without surgery, radiotherapy or chemotherapy on
the basis that older women are more likely to have cancers with oestrogen receptors and will therefore respond well to treatment. In
addition they were thought less suitable for major surgery because of other existing health issues. However, a tumour will often only
respond to this treatment for between 18 and 24 months, and those women who relapse will have to consider additional hormone
treatment or opt for surgery or radiotherapy at a greater age. The long-term data suggest that, at 12 years of follow-up, more elderly
women treated by primary tamoxifen alone will suffer a progression of their cancer than those who have had surgery.
We undertook this review to assess the evidence for the clinical effectiveness of surgery (with or without endocrine therapy) compared
with primary endocrine therapy in the treatment of operable breast cancer in women aged 70 years and over. Based on seven trials
and an estimated 1081 deaths in 1571 women, the results of this review showed no beneﬁt in respect to survival for either surgery or
primary endocrine therapy. However, women who had surgery were less likely to relapse than women on primary endocrine therapy.
The authors conclude that surgery controls breast cancer better than tamoxifen alone in older women but does not extend survival. Both
interventions were associated with adverse events. Tamoxifen-related adverse effects included hot ﬂushes, skin rash, vaginal discharge,
indigestion, breast pain, sleepiness, headache, vertigo, itching, hair loss, cystitis, acute thrombophlebitis, nausea, and indigestion.
Surgery-related adverse effects included tingling or numbness on the arm on the side of the surgery, and psychosocial problems. On
this basis, primary endocrine therapy should only be offered to women with oestrogen receptor (ER)-positive tumours who are unﬁt
for, or who refuse surgery. We need further trials to evaluate the clinical effectiveness of other agents such as aromatase inhibitors for
use as primary endocrine therapy for an inﬁrm older population with ER-positive tumours.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Surgery compared to primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
Patient or population: Women (70 years plus )with operable primary breast cancer
Settings: Hospital
Intervention: Surgery
Comparison: Primary endocrine therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Primary endocrine ther-
apy
Surgery
Survival - overall
Follow-up: 0 - 28 years
Study population HR 0.98
(0.81 to 1.20)
495
(3 studies)
⊕⊕©©
low1
862 per 1000 854 per 1000
(826 to 877)
Moderate
969 per 1000 967 per 1000
(960 to 973)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unselected Oestrogen receptor status. Variability of surgery undertaken. No co-morbidity assessment undertaken.
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B A C K G R O U N D
Description of the condition
Invasive breast cancer occurswhenuncontrolled, abnormal growth
and division of cells in either the lobules or the ducts of the breast
spread to the surrounding tissue. TheUnion InternationaleContre
le Cancer (UICC) staging system for breast cancer reﬂects how,
when left untreated, cancer cells can spread locally to the breast
tissue and the lymph glands in the armpit (Stages 1 to 3) and
through the bloodstream and lymphatic system to other parts of
the body (Stage 4). UICC Stages 1 to 3 are known as ’early breast
cancer’ (UICC 2009).
Breast cancer is the most common type of cancer in women. In
2008, there were an estimated 1.38 million new cases and over
458,000 deaths (Globocan 2010). Up to 30% of all breast cancers
are reported to occur in the over-70 years age-group and 48% in
the over-65s (Sader 1999;Wanebo 1997). An ageing population in
developed countries may see these percentages increase still further
(Silliman 1993). However, owing to omission of the elderly from
the majority of clinical trials (Bayer 2000; Bugeja 1997), there are
few data deﬁning the optimum treatment for breast cancer in the
elderly.
Description of the intervention
The standard treatment for early-stage breast cancer in women of
all ages was surgery until the late 1970s, with good results reported
(Kesseler 1978). Primary endocrine therapy was ﬁrst described
in the early 1980s as an alternative to standard therapy for older
women (Bradbeer 1983; Preece 1982). Treatment involved the sole
use of a drug called tamoxifen, without surgery, radiotherapy or
chemotherapy. Tamoxifen is an anti-oestrogen. It acts by blocking
the oestrogen receptor (ER) in the nucleus of breast cancer cells.
If oestrogen binds to these receptors, the breast cancer cells are
stimulated to grow. Blocking of this receptor causes the cancer to
stop growing and regress, in most cases. The majority (70%) of
breast cancers have oestrogen receptors but the percentage does
vary with age. Older women are much more likely to have cancers
with oestrogen receptors (Diab 2000; McCarty 1983).
How the intervention might work
Older women who were started on tamoxifen primary endocrine
therapy in these early studies responded relatively well to the treat-
ment. The cancer in the breast would either shrink or fail to
progress in 75% of women. The treatment was well-tolerated and
enabled the avoidance of complications related to surgery. This
treatment option was, therefore, enthusiastically adopted by both
surgeons and their elderly patients. The treatment was reﬁned by
the use of oestrogen receptor status to select those likely to respond.
A good response can be expected in between 79% and 83% of
women who are moderately or strongly ER-positive, compared to
a 90% to 100% progression rate in those with absent ER staining
(Gaskell 1989; Gaskell 1992).
However, the mean duration of response to primary endocrine
therapy is only 18 to 24 months. In consequence, women who
relapse are then faced with the prospect of changing to second-
line hormonal therapy, surgery or radiotherapy, at a greater age,
and run the risk that the disease may become inoperable. Overall,
when long-termdata are studied, 81%of elderly women treated by
primary tamoxifen will go on to develop progression after 12 years
of follow-up compared with 38% following mastectomy alone
(Kenny 1998). As yet, there is no clear consensus as to whether or
not there is a survival advantage for tamoxifen or surgery in this
age group. It would seem, on the basis of current evidence, that
there is little to recommend the use of tamoxifen alone for the
primary treatment of operable primary breast cancer in all but the
very inﬁrm.
The trend towards primary tamoxifen treatment was based on
the premise that older women are less likely to be ﬁt for surgery.
The incidence of signiﬁcant co-morbidity is greater in the elderly
(Satariano 1994), which is thought to render general anaesthe-
sia more hazardous. However, the majority of elderly women will
be ﬁt for surgery under general anaesthesia because mastectomy,
even when combined with axillary clearance, has a low morbidity
and mortality. The recent UK National Mastectomy and Recon-
struction Audit has demonstrated that overall the mortality for
breast surgery is 0.26% (NHSIC 2011). Review of articles report-
ing treatment speciﬁcally in the over-70 age group by wide local
excision, either under local or general anaesthesia, reports only two
deaths in 615 women undergoing surgery (0.3%) (Wyld 2003).
The recent trend towards sentinel node biopsy rather than a full
axillary clearance of all axillary nodes, a much less invasive op-
eration, would further reduce the risks of surgery (Burak 2002).
In addition, even a mastectomy can usually be performed under
local anaesthesia (Oakley 1996), reducing risks still further. How-
ever, many older women may be keen to avoid surgery for diverse
reasons when offered a choice of surgery or primary endocrine
therapy, such as avoidance of hospitalisation, fear of mutilation,
or desire to maintain independence (Husain 2008).
Why it is important to do this review
It is difﬁcult to assess howwidespread the use of primary endocrine
therapy is worldwide. It is apparently not a treatment option in the
USA (Diab 2000) and is rarely used in Australia (Craft 2000). In
Europe, reports of primary endocrine therapy usage for the elderly
vary greatly; from 3% in Italy (Crivellari 1991), 9% in France
(Garbay 1998), 16% in the Netherlands (Van Dalsen 1995), 26%
in Eire (Hooper 2002), up to 32% in Sweden (Bouchardy 2003).
By contrast, audits of current UK practice have conﬁrmed that the
use of primary endocrine therapy is widespread, with 42% of all
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women over 70 being treated in this way (Wyld 2004) and 55%
of women over the age of 80 (Monypenny 2003). In addition, in
many of these cases there is no documentation of co-morbidity to
justify its use (Wyld 2004). It is therefore important to establish
whether this type of treatment is justiﬁable for older women with
breast cancer and, if it is, under what circumstances.
O B J E C T I V E S
To systematically review the evidence for the clinical effectiveness
of surgery (with or without endocrine therapy) in comparison to
primary endocrine therapy in the treatment of operable breast
cancer in women aged 70 years and over, both in terms of local
progression and mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Women aged 70 years or over with clinically-deﬁned operable pri-
mary breast cancer, that is, primary tumour not ﬁxed to underly-
ing structures (including the TNM classiﬁcation T1 - T3 and T4b
where there is only minor skin involvement and N0-1, mobile
lymph nodes (UICC 2009). We planned the following age-based
subgroup analyses: 70 to 79 years; 80 years and over.
Types of interventions
1. Surgery alone versus primary endocrine therapy.
With the following subgroups for the surgery arm:
• mastectomy alone with or without axillary surgery (where
’axillary surgery’ includes axillary clearance or sampling);
• wide local excision alone, with or without axillary surgery,
with the following further subgroups: margins unspeciﬁed;
margins speciﬁed and adequate (histologically clear, as speciﬁed
in Smitt 1995); margins speciﬁed but inadequate by modern
standards;
• wide local excision and deep x-ray therapy or radiotherapy,
with or without axillary surgery, with the following further
subgroups: margins unspeciﬁed; margins speciﬁed and adequate
(histologically clear); margins speciﬁed but inadequate by
modern standards.
With the following subgroups for both arms:
• oestrogen receptor (ER) status: positive; negative or
unknown;
• progesterone receptor (PR) status: positive; negative or
unknown;
• clinical stage at diagnosis, to include size of primary tumour
and whether nodes are palpable, or unknown.
2. Surgery plus adjuvant endocrine therapy versus primary en-
docrine therapy.
With the following subgroups for the surgery arm:
• mastectomy alone, with or without axillary surgery;
• wide local excision alone, with or without axillary surgery,
with the following further subgroups: margins unspeciﬁed;
margins speciﬁed and adequate (histologically clear); margins
speciﬁed but inadequate by modern standards;
• wide local excision and deep x-ray therapy or radiotherapy,
with or without axillary surgery, with the following further
subgroups: margins unspeciﬁed; margins speciﬁed and adequate
(histologically clear); margins speciﬁed but inadequate by
modern standards.
With the following subgroups for the primary endocrine therapy
arm:
• oestrogen receptor (ER) status: positive; negative or
unknown;
• progesterone receptor (PR) status: positive; negative or
unknown;
• clinical stage at diagnosis, to include size of primary tumour
and whether nodes are palpable, or unknown.
Types of outcome measures
Primary outcomes
1. Overall survival (interval between start of treatment and
participant’s death; cause of death where available).
2. Progression-free survival (interval between start of
treatment and need for second-line treatment/palliative
treatment/recurrence/death from any cause).
Secondary outcomes
1. Adverse effects (number of surgical complications/primary
endocrine therapy-related side effects, including hot ﬂushes,
nausea, vomiting, vaginal discharge, vaginal bleeding,
thrombosis, endometrial carcinoma, visual problems, skin
rashes).
2. Local disease control (interval between start of treatment
and need for second-line treatment/palliative treatment/
recurrence; speciﬁed whether local disease has recurred in the
breast/mastectomy scar or axilla).
3. Distant metastasis-free interval (interval between start of
treatment and the development of metastatic disease).
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4. Quality of life (however measured).
Search methods for identification of studies
Electronic searches
For the 2013 review update, we undertook the following searches:
• The Cochrane Breast Cancer Group (CBCG) Specialised
Register on the 27 March 2013 (details of the search strategies
used by the group for the identiﬁcation of studies and the
procedure used to code references are outlined in the group’s
module at www.mrw.interscience.wiley.com/cochrane/clabout/
articles/BREASTCA/frame.html). We identiﬁed studies with the
text words ’early breast cancer’, ’endocrine therapy’,
’psychosocial’ or ’surgery’ for consideration.
• Cochrane Central Register of Controlled Trials
(CENTRAL), The Cochrane Library 2013, Issue 3 (Appendix 1).
• MEDLINE (via OvidSP) from 2008 until 27 March 2013.
Appendix 2.
• EMBASE (via Embase.com) from 2008 until 27 March
2013. Appendix 3.
• The WHO International Clinical Trials Registry Platform
(ICTRP) search portal (apps.who.int/trialsearch/Default.aspx )
for all prospectively registered and ongoing trials on the 27
March 2013. See Appendix 4.
• ClinicalTrials.gov (clinicaltrials.gov/ct2/home) until 27
March 2013. See Appendix 5.
Searching other resources
We checked the reference lists of identiﬁed trials and reviews to
identify any additional eligible studies.
Data collection and analysis
Selection of studies
Assessing trials for eligibility
We applied the selection criteria, as deﬁned above, to each trial.
1. We justiﬁed any exclusions of a potentially eligible trial in the
ﬁnal report.
2. We used trial publications to assess the trial’s eligibility with
the results section (and any other area where results may have
appeared) masked.
3. If a trial had not been published, we obtained information from
the trial protocol or next best available resource.
4. Where necessary, and possible, we sought additional informa-
tion from the principal investigator of the trial concerned.
Quality control and peer review
1. We considered only evidence provided by randomised con-
trolled trials.
2. Two reviewers, JM and LW, independently assessed each poten-
tially eligible trial for inclusion in the updated review.
3. We assessed trial publications for eligibility with the results
section (and any other area where results may appear) masked.
4. Where necessary, we sought additional information from the
principal investigator of the trial concerned. We copied any addi-
tional information obtained from trial investigators to the Man-
aging Editor of the CBCG for inclusion in the specialised register.
Data extraction and management
Two review authors (JM and LW) independently extracted data
from the included studies using a paper data extraction form. JM
entered and analysed data inCochrane ReviewManager 5 software
(RevMan 2012).
Several studies had more than one publication. This 2013 review
update found only new publications with updated results from
already included studies. We extracted data from these recent pub-
lications and added them or replaced previously extracted data
where appropriate. We considered the most recent publication
containing the relevant outcome data to be the primary reference
for each study. This is indicated by an asterisk in the Reference
section.
Assessment of risk of bias in included studies
See ’Risk of bias’ tables in the Characteristics of included studies
section.
The review authors independently evaluated the quality of the
included trials, resolving discrepancies by consensus. We sought
clariﬁcation from the trial author if the published data provided
inadequate information for the review.
(1) Selection bias (Allocation concealment)
Allocation concealment is regarded as particularly important in
protecting against bias. We assessed and graded the quality of the
randomisation processed accordingly (Higgins 2011):
Low risk: Clearly adequate concealment.
Unclear risk: Possibly adequate, or insufﬁcient information to
judge.
High risk: Clearly inadequate concealment.
(2) Performance bias and Detection bias (blinding):
Owing to the nature of the interventions, it is not possible to blind
either participants, care givers or outcome assessment to the type
of intervention received.
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(3) Attrition bias (intention-to-treat analysis):
We assessed and graded attrition bias as follows (Higgins 2011):
Low risk: We analysed all participants in the treatment group
to which they were allocated, regardless of whether or not they
received the allocated intervention.
Unclear risk:We could not determine if participants were analysed
according to the intention-to-treat principle after contact with the
authors.
High risk: Some participants are not analysed in the treatment
group to which they were randomised because they did not receive
the study intervention; they withdrew from the study; or because
of protocol violation.
(4) Reporting bias:
Owing to the limited number of studies, it was not possible to
adequately assess for reporting bias using funnel plot asymmetry
assessment. We therefore reviewed each study according to the
appropriateness of the outcomes reported.
Low risk: Data were fully reported on all relevant outcomes.
Unclear risk: Relevant outcomes were reported but usable data
were not presented.
High risk: No relevant outcomes were reported.
Overall quality assessment:
From the quality assessment of the trials, we summarised the
potential risk of bias into three categories as described by The
Cochrane Collaboration’s ’Risk of bias’ tool (Higgins 2011):
Low risk of bias: plausible bias unlikely. All of the criteria met,
therefore unlikely to seriously alter the results.
Moderate risk of bias: plausible bias. One or more criteria partly
met, or one not met, which therefore raises some doubt about the
results.
High risk of bias: plausible bias. Two or more criteria not met.
Seriously weakens conﬁdence in the results.
Measures of treatment effect
Two review authors (JM and LW) independently assembled the
most complete dataset feasible.
1.We statistically synthesised results of eligible studies (meta-anal-
ysis).
2. We conducted all analyses on an intention-to-treat basis.
3. We conducted time-to-event analyses for time to death (sur-
vival) and time to disease progression (progression-free survival).
We synthesised (meta-analysed) trial outcome data, if appropriate
(i.e., there was more than one trial with similar populations, in-
terventions and outcomes) and possible (i.e. there were adequate
data). In the absence of published summary statistics (i.e., hazard
ratios (HRs) and conﬁdence intervals (CIs)), we sought these rel-
evant summary statistics or individual patient data from the trial-
ists. All analyses were on an intention-to-treat principle. For time-
to-event analyses, we calculated combined hazard ratios and 95%
conﬁdence intervals using the O-E and variance methods in The
Cochrane Collaboration Review Manager 5 software (RevMan
2012). This uses the log hazard ratio and its variance from the
relevant outcome of each trial. These, in turn, we calculated us-
ing a Microsoft Excel spreadsheet authored by Matt Sydes of the
MRC Clinical Trials Unit, which incorporates Parmar’s methods
for extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints (Parmar 1998).
We estimated the log hazard ratio and its variance by two of Par-
mar’s hierarchy of methods depending on the availability of sum-
mary statistics. Where possible, we used the methods described
in subsection 4 of Parmar 1998, which estimates the variance of
the log hazard ratio indirectly from the hazard ratio and its 95%
conﬁdence interval. If the study did not report the HR or CI, we
employed the methods described in subsection 5 (Parmar 1998),
which estimates the log hazard ratio and its variance from survival
curves. Where event numbers were not published, we reported the
’effective number of deaths’ for each arm, as calculated in theMRC
spreadsheet, in the Review Manager forest plots. These estimates
in no way affect the calculation of the hazard ratio and its variance
and should be considered illustrative. Additional Table 1 (’Source
data for comparisons’) records the summary statistics used for this
purpose.
We reported ratios of treatment effects, so that HRs less than 1.0
favour surgery or surgery plus endocrine therapy, and values greater
than 1.0 favour primary endocrine therapy.
4. We made a decision regarding whether and how to combine
quality-of-life outcomes depending on whether and how each trial
collected this information.
Unit of analysis issues
There were no unit of analysis issues.
Dealing with missing data
Several trials did not report relevant survival data, and we therefore
contacted the original investigators (performed by JM and authors
of the original review: DH, LW, MR).
In the 2013 update, there were no missing data issues and we
obtained anonymised individual patient data wherever possible.
Assessment of heterogeneity
We assessed heterogeneity between trial results using the Chi² test
and the I² measurement. The Chi² test assesses the amount of
variation in a set of trials. Small P values suggest that there is
more heterogeneity present than would be expected by chance.
Chi² is not a particularly sensitive test: a cut-off P value less than
0.10 is often used to indicate signiﬁcance, but lack of statistical
signiﬁcance does not mean there is no heterogeneity. I² is the
proportion of variation that is due to heterogeneity rather than
7Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
chance (Higgins 2003). Large values of I² suggest heterogeneity. I²
values of 25%, 50%, and 75% could be interpreted as representing
low, moderate, and high heterogeneity.
Assessment of reporting biases
Owing to the small number of included studies, it was not possible
to use funnel plot asymmetry to assess for the presence of reporting
bias as recommended in the Cochrane Handbook for Systematic
Reviews of Interventions 5.1.0. (Higgins 2011).
Data synthesis
For the primary outcomes of overall and progression-free survival
(i.e. time-to-event analyses), we calculated combined hazard ra-
tios and 95% conﬁdence intervals using Exp [(O-E)/V] meth-
ods in The Cochrane Collaboration software Review Manager 5
(RevMan 2012), using a ﬁxed-effect model (Peto method - Yusuf
1985, as described in the Cochrane Handbook for Systematic Re-
views of Interventions; Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We analysed data according to those trials randomising to surgery
alone versus primary endocrine therapy, and those trials randomis-
ing to surgery plus endocrine therapy versus primary endocrine
therapy. We had planned to conduct subgroup analyses; however
owing to the small number of trials with limited data, this was not
possible.
Sensitivity analysis
Wewere unable to conduct the proposed sensitivity analysis (based
on trial quality), because of the small number of trials.
R E S U L T S
Description of studies
Results of the search
For this 2013 review update, we reviewed 1761 references. Of
these, 1760 could be excluded based on information in the title
or abstract. We retrieved one full-text article for further examina-
tion and identiﬁed one further publication through handsearch-
ing. Both of these publications pertained to studies already in-
cluded in the previous review (Nottingham 1; St Georges). The
searches identiﬁed no new studies.
For the previous version of this review, on 13th November 2007,
the Cochrane Breast Cancer Group Specialised Register con-
tained 838 references coded to studies of ’EARLY BREAST
CANCER’, ’ENDOCRINETHERAPY’, ’PSYCHOSOCIAL’ or
’SURGERY’. Of these, we excluded 810 based on information
in the title or abstract. The remaining 28 references reported on
seven potentially eligible studies for the review. We excluded none
of these studies. We retrieved ﬁve additional papers relating to the
same trials through handsearching.
Included studies
We include seven studies in total.
We identiﬁed three eligible trials addressing surgery versus primary
endocrine therapy, all of which reported data. In each case the
endocrine therapy used was tamoxifen.
We identiﬁed four eligible trials addressing surgery plus endocrine
therapy versus primary endocrine therapy, of which three have
reported data; there are currently no data from one (Naples) in a
form that can bemeta-analysed. In each case the endocrine therapy
used was tamoxifen.
Not all trials identiﬁed provided information on all outcomes.
Excluded studies
We excluded none of the potentially eligible studies identiﬁed by
the search.
Risk of bias in included studies
It was not possible to accurately assess the quality of all studies
owing to lack of information in the published articles. Please see
Characteristics of included studies and Figure 1 for more details.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence Generation:
Three trials provided adequate information on the generation of
the allocation sequence and we graded these as being low risk of
bias (CRC; Nottingham 1; GRETA), with the rest being graded
as unclear risk of bias (EORTC 10851; Naples; Nottingham 2; St
Georges).
Allocation Concealment:
Three trials provided adequate information to be graded as be-
ing low risk of bias (CRC; EORTC 10851; GRETA), with the
rest being graded as unclear risk of bias (Naples; Nottingham 1;
Nottingham 2; St Georges).
Blinding
Owing to the nature of the interventions, neither participants,
clinicians nor outcome assessors could be blinded in these studies.
In a comparison between a surgical treatment and a medication, it
will be clear to both participants and clinicians which treatment a
participant has been assigned to, and blinding was therefore con-
sidered to be at unclear risk of bias. We made no further assess-
ment.
Incomplete outcome data
All studies reported on the relevant outcomes.
Selective reporting
All studies reported on our primary outcome, overall survival,
although not all could be included in the meta-analysis owing to
non-comparable presentation of data. All studies were deemed at
low risk of bias except Naples, which was graded as unclear risk
due to lack of published information.
Other potential sources of bias
We did not note other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Surgery
compared to primary endocrine therapy for operable primary
breast cancer in elderly women (70 years plus); Summary of
findings 2 Surgery plus endocrine therapy compared to primary
endocrine therapy for operable primary breast cancer in elderly
women (70 years plus)
Results for the two comparisons (surgery versus primary endocrine
therapy; surgery plus endocrine therapy versus primary endocrine
therapy) are considered separately.
1. Surgery versus primary endocrine therapy
Survival - overall
The ﬁrst primary analysis of overall effect using hazard ra-
tios derived from published survival curves (EORTC 10851;
Nottingham 1; St Georges) involved three trials (495 women).
The calculated hazard ratio showed no signiﬁcant difference be-
tween the two treatment arms for this outcome (HR 0.98 , 95%
CI 0.81 to 1.20, P = 0.85; Analysis 1.1; Figure 2). There was only
minor heterogeneity (Chi² = 2.67, df = 2, P = 0.26; I² = 25%).
Figure 2. Forest plot of comparison: 1 Surgery versus primary endocrine therapy, outcome: 1.1 Survival -
overall.
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There were insufﬁcient data to justify any quantitative analysis of
prospectively identiﬁed subsets.
Progression-free survival
Only one trial, EORTC 10851, reported data related to this out-
come.We calculated a hazard ratio frompublished summary statis-
tics using the method described by Parmar 1998, which favoured
surgery (HR 0.55, 95% CI 0.39 to 0.77; P = 0.0006; 164 partic-
ipants).
Adverse effects
There were insufﬁcient data to justify any quantitative analysis of
this outcome.Neither EORTC10851 norNottingham 1 reported
on side effects. In the St Georges trial no participant discontinued
treatment with primary endocrine therapy. Eight participants had
a total of 10 side effects, including hot ﬂushes, skin rash, vaginal
discharge, indigestion, breast pain and sleepiness.
Local disease control
Estimates of effect were available from published survival curves
(EORTC10851;Nottingham 1) and from anonymised individual
patient data (St Georges) for three trials. In one trial (St Georges),
surgical margins were inadequate by modern standards; this trial
had also introduced informative censoring. All three trials had
substantial competing risks, in some cases as high as 50%. In our
original review, the Cochrane Breast Cancer Group’s statisticians
recommended that the potential for bias was considerable, and we
present neither a meta-analysis, nor individual results from these
trials. We discuss competing risks, heterogeneity of interventions
and informative censoring below.
Distant metastasis-free interval
Estimates of effectwere available fromone published survival curve
(EORTC 10851) and from anonymised individual patient data
(St Georges) for two trials. Because of heterogeneity between the
two trials and competing risks within each analysis, the Cochrane
Breast Cancer Group’s statisticians recommended that the poten-
tial for bias was considerable, and we do not present a meta-
analysis. Distant failure was reported as a ﬁrst event in 15/82
(surgery) and 7/82 (primary endocrine therapy) women in Table
2 (Fentiman 2003, page 314); however 16/82 (surgery) and 19/
82 (primary endocrine therapy) observed events were reported be-
neath the Kaplan-Meier curve in Figure 4 (Fentiman 2003, page
313). Therefore, this hazard ratio reported above incorporates dis-
tant metastases recorded both as a ﬁrst event, and following or
simultaneously with a local progression. Despite the competing
risk and the issue of multiple events, the Cochrane Breast Cancer
Group’s statisticians did not oppose calculation of a hazard ratio
for EORTC 10851 (HR 0.77, 95% CI 0.37 to 1.58, P = 0.47,
164 women) from published summary statistics using the method
described by Parmar 1998. We do not present a hazard ratio for
the St Georges trial because it reports only ﬁrst events, since surgi-
cal margins were inadequate by modern standards, and because of
informative censoring. We discuss competing risks, heterogeneity
of outcome measurement and informative censoring below.
Quality of life
None of the trials reported any data pertinent to this outcome.
2. Surgery plus endocrine therapy versus primary
endocrine therapy
Survival - overall
The ﬁrst primary analysis of overall effect using hazard ratios de-
rived from published survival curves (Nottingham 2) or directly
from trialists (CRC;GRETA) involved three trials (1076 women).
There was a non-signiﬁcant trend in favour of surgery plus en-
docrine therapy (HR 0.86, 95% CI 0.73 to 1.00; P = 0.06; Anal-
ysis 2.1; Figure 3). There was no signiﬁcant heterogeneity across
trials (Chi² 2.05, df 2, P = 0.36, I² = 3%).
Figure 3. Forest plot of comparison: 2 Surgery plus endocrine therapy versus primary endocrine therapy,
outcome: 2.1 Survival - overall.
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Survival - by oestrogen receptor status
Limited data for subgroup analysis by oestrogen receptor status
were available. In the one trial where oestrogen receptor status was
positive for all participants (Nottingham 2: 147 women), there
was no signiﬁcant difference between the interventions (HR 0.80,
95% CI 0.28 to 2.32; P = 0.68). In the remaining two trials
(CRC;GRETA: total 929 women) the oestrogen receptor status of
participantswas unknown.Here therewas no signiﬁcant difference
between interventions (HR 0.86, 95% CI 0.73 to 1.00; P = 0.06).
There was no signiﬁcant heterogeneity across trials (Chi² 2.04, df
1, P = 0.15, I² = 50.9%).
Survival - by age
Age-related subgroup analysis was not possible on the basis of
published data. In a conference abstract (Mustacchi 1998), trialists
fromGRETA and CRC reported analyses of combined individual
patient data from both trials. They reported that participant age
was the most important determinant of survival in later years (75
years plus). In those aged between 70 and 75 years, initial surgery
(rather than primary endocrine therapy) determined survival.
Survival - breast cancer-specific
We obtained unpublished hazard ratios for breast cancer-speciﬁc
survival data from two trials (CRC; GRETA), but were unable to
conduct a subgroup meta-analysis as there were no data on the risk
of a non-breast cancer-related death. A published meta-analysis of
individual patient data from the CRC and GRETA studies found
a signiﬁcant trend in favour of surgery plus endocrine therapy (HR
0.70, 95% CI 0.51 to 0.95) (Mustacchi 1998).
Progression-free survival
Only one trial (GRETA), reported data related to this outcome.
We calculated a hazard ratio from published summary statistics
using themethod described by Parmar 1998: this favoured surgery
plus endocrine therapy (HR 0.65, 95% CI 0.53 to 0.81, P =
0.0001; 474 participants).
Adverse effects
There were insufﬁcient data to justify any quantitative analysis
of this outcome. The CRC trial did not quantify adverse events,
only reporting that one woman from the primary endocrine ther-
apy arm had to drop out of the trial because of endocrine ther-
apy-related adverse effects. Nottingham 2 did not report adverse
events. In the GRETA trial, all participants in the surgery plus
primary endocrine therapy arm who had axillary clearance had
paraesthesia on the ipsilateral arm and lateral thoracicwall. Tamox-
ifen-related toxicity was similar between the two groups and in-
cluded headache, vertigo, itching, hair loss, cystitis, vaginal bleed-
ing, acute thrombophlebitis, nausea, and indigestion.
Local disease control
We conducted an analysis of overall effect, using hazard ratios de-
rived from one unpublished (CRC) and one published (GRETA)
survival curve involving two trials (929 women). This showed a
signiﬁcant difference in favour of surgery plus endocrine therapy
(HR 0.28, 95%CI 0.23 to 0.35, P < 0.00001; Analysis 2.2; Figure
4). There was signiﬁcant heterogeneity across trials (Chi² 2.90, df
1, P = 0.09, I² = 66%), which is discussed below. We did not in-
clude data from Nottingham 2 in this analysis, as reported results
were immature compared to the other two trials.
Figure 4. Forest plot of comparison: 2 Surgery plus endocrine therapy versus primary endocrine therapy,
outcome: 2.2 Local disease control.
There were insufﬁcient data to justify any quantitative analysis of
prospectively identiﬁed subsets. However, one trial (Nottingham
2), which recruited only women with ER-positive tumours re-
ported better local control in the surgery plus endocrine arm. An-
other trial (CRC) reported this outcome by type of surgery, com-
paring both mastectomy (52 of 225 women) and breast-conserv-
ing surgery (159 of 225) against the same population of primary
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endocrine therapy (230 women). The trialists reported better local
disease control for bothmastectomy and breast-conserving surgery
than for primary endocrine therapy. Note that 14 participants in
the surgery arm did not receive their planned surgery and were
excluded from this subgroup analysis.
Distant metastasis-free interval
We obtained summary data from one trialist (GRETA); however,
Cochrane Breast Cancer Group statisticians advised that the con-
ﬁdence interval was too narrow to be reliable, and that until we
were able to clarify the quality of these data we should not report
the outcome.
Quality of life
There were insufﬁcient data to justify any quantitative analy-
sis of this outcome. However, the CRC group used the General
Health Questionnaire 28 (GHQ-28: Goldberg 1970), which de-
tects psychological morbidity, and a socio-demographic question-
naire, which investigated levels of domestic support and social iso-
lation. At three months after start of treatment, the surgery group
had more psychosocial morbidity (P = 0.03). However, there was
no difference between the surgery and primary endocrine therapy
groups at two years (Fallowﬁeld 1994).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Surgery plus endocrine therapy compared to primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
Patient or population: Women (70 years plus) with operable primary breast cancer
Intervention: Surgery plus endocrine therapy
Comparison: Primary endocrine therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Primary endocrine ther-
apy
Surgery plus endocrine
therapy
Survival - overall
Follow-up: 0 - 12 years
Study population HR 0.86
(0.73 to 1)
1076
(3 studies)
⊕⊕©©
low1
617 per 1000 581 per 1000
(541 to 617)
Moderate
613 per 1000 577 per 1000
(536 to 613)
Local disease control
Follow-up: 0 - 12 years
Study population HR 0.28
(0.23 to 0.35)
929
(2 studies)
⊕⊕⊕⊕
high
452 per 1000 187 per 1000
(159 to 224)
Moderate
452 per 1000 188 per 1000
(159 to 224)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Unselected Oestrogen receptor status. Variability of surgery undertaken. No co-morbidity assessment undertaken.
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D I S C U S S I O N
Summary of main results
This study has demonstrated that primary endocrine therapy is
inferior to surgery with endocrine therapy for the local control of
breast cancer in ER-unselected, medically ﬁt older women. It is
also independent of the type of surgery, with both mastectomy
and wide excision (without adjuvant radiotherapy) achieving su-
perior local control. However, surgical treatment does not result
in signiﬁcantly better overall survival.
Overall completeness and applicability of
evidence
The results of this review need to be read bearing in mind that
they are derived from a small number of individually underpow-
ered studies. Additionally, there are four areas where treatment
regimens in the trials do not necessarily coincide with modern
clinical practice. Therefore, the appropriateness of the following
should be questioned: (1) endocrine therapy for women with ER-
negative tumours; (2) surgery without adjuvant endocrine ther-
apy; (3) primary endocrine therapy where the individual is ﬁt for
and agreeable to surgery; (4) new endocrine therapies.
(1) Oestrogen receptor status
Most of the included trials recruited women regardless of oestro-
gen receptor status. However, only 85% to 90% of women in this
age group have ER-positive tumours (Diab 2000). For those with
ER-negative tumours, endocrine therapy was not an active inter-
vention and such treatment is not in line with modern clinical
practice.
Their inclusion may also have biased the results of the meta-analy-
sis, although the extent is difﬁcult to assess. Had women with ER-
negative tumours been excluded from the studies (which would
have been a fairer comparison), the primary endocrine therapy arm
might have performed better against the surgery plus endocrine
therapy arm, although it is unlikely that the considerable local
control advantage conferred by surgery would be overcome. Only
Nottingham 2, a trial comparing surgery with adjuvant endocrine
therapy against endocrine therapy alone, recruited exclusively par-
ticipants with ER-positive tumours. Local control was inferior in
the primary endocrine therapy group despite this.
(2) Surgery without adjuvant endocrine therapy
Three of the trials included in this study (EORTC 10851;
Nottingham 1; St Georges) did not include adjuvant endocrine
therapy after surgery. However, it is considered best practice to-
day for women with ER-positive tumours to receive adjuvant en-
docrine therapy in addition to surgery (NICE 2002). The results
of this study showed no difference in overall survival where surgery
alone was compared with primary endocrine therapy (HR 0.98,
95% CI 0.81 to 1.20, P = 0.85). Where surgery and adjuvant
endocrine therapy were compared to primary endocrine therapy,
the direction of effect favoured surgery; however, this was only
of borderline signiﬁcance (HR 0.86, 95% CI 0.73 to 1.00, P =
0.06). As discussed above, it is possible that selection of ER-pos-
itive women might improve the relative effectiveness of primary
endocrine therapy.
(3) Co-morbidity
Primary endocrine therapy for the treatment of operable breast
cancer in older women is still in widespread use in the UK
(BCCOM 2007; Monypenny 2003; Wyld 2004); however, the
populations represented in the included studies may not be typical
of those who receive such treatment today. The women recruited
to these studies were, by deﬁnition, ﬁt for surgery and therefore
their life expectancy would have been good (Exterman 2000) and
the surgical risks low. The reality of current practice in many units
in the UK is to restrict primary endocrine therapy to those women
in whom the risks of surgery are high or who would be expected
to have a reduced life expectancy because of co-morbid diseases
(Wyld 2004).
It is worth noting that none of the included studies controlled for
participant co-morbidity, which has a signiﬁcant inﬂuence on sur-
vival in this age group (Satariano 1994). Thus we see that breast
cancer-speciﬁc survival is improved in those randomised to surgery
plus endocrine therapy compared to those on primary endocrine
therapy (HR 0.70, 95% CI 0.51 to 0.95: Mustacchi 1998). As
already noted, difference in overall survival still favours the surgery
arm but is only of borderline signiﬁcance. This serves to empha-
sise that, even among those ﬁt for surgery in this age group, a sig-
niﬁcant proportion of participants still die of co-morbid diseases,
so reducing the relative advantages of any breast cancer therapies
(Satariano 1994).
(4) Different endocrine therapies
In each included study the endocrine therapy used was tamox-
ifen, an oestrogen-receptor antagonist. Since these studies were
designed, new endocrine therapies for the treatment of ER-posi-
tive breast cancer have become available. These are the aromatase
inhibitors anastrozole, letrozole and exemestane. Letrozole has
been shown to be superior to tamoxifen in the neoadjuvant set-
ting (Eiermann 2001; Ellis 2011) and in the metastatic setting
(Mouridsen 2003). Anastrazole is superior to tamoxifen in the ad-
juvant setting (ATAC 2005). It is possible that primary endocrine
therapy using these newer agents may be even more attractive for
older women who are unﬁt for surgery. This hypothesis should be
tested in a randomised controlled trial (RCT), although a recent
attempt to run a multicentre UK RCT comparing surgery plus
an adjuvant aromatase inhibitor versus primary endocrine ther-
apy with an aromatase inhibitor failed to recruit, due to women
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refusing randomisation and preferring to make their own choice
of treatment (Reed 2009).
Quality of the evidence
In some cases, the internal validity of the included trials was af-
fected by competing risks and informative censoring. Heterogene-
ity between trials, in terms of interventions and outcome assess-
ment, also made the review team’s assessment of some outcomes
difﬁcult.
(1) Competing risks
The calculation of the Kaplan-Meier (KM) probabilities assumes
that failure from local recurrence is still possible beyond the time
of censoring. For those participants who failed from other causes
(e.g., death without failing) this is called the ’competing risk’. Cen-
soring participants who fail from competing risks is not appropri-
ate as it gives an underestimate of the probability of local failure
by treating those cases who have not failed locally and are alive
the same as those who have not failed locally but have died. This
approach is clearly undesirable.
Despite the fact that none of the trials adjusted for competing risks
when calculating local disease control, Cochrane Breast Cancer
Group statisticians advised us that the Kaplan-Meier plots and
estimates of the hazard ratio would be more likely to be valid if
the following conditions were met:
(a) the rate of deaths without breast cancer recurrence (not nec-
essarily the same as non-breast cancer-related death) was similar
and accounted for a small percentage of the deaths in both arms
(maybe less than 10%); and,
(b) the duration over which deaths without recurrence were hap-
pening was roughly the same (the competing risk of deaths is uni-
form over the two arms across the follow-up period).
In none of the trials can we be sure that these conditions are met.
Therefore, the results in the trial reports for this outcome must
be read with caution. Not only should these trials not be meta-
analysed but Cochrane Breast Cancer Group statisticians advise us
it would be inappropriate to further disseminate their results for
this particular outcome, as it represents a potentially misleading
estimate of effect. The same issue arises with distantmetastasis-free
interval for the surgery alone versus primary endocrine therapy
comparison.
(2) Informative censoring
The Kaplan-Meier methods used to calculate time to local or dis-
tant recurrence assume that censoring is non-informative, i.e., that
the fact that a person is censored at a given time is independent
of their potential outcome. In the St Georges trial, participants
are censored at the time of the last clinical examination. If we
assume that those who have progressed are more likely to attend
follow-up clinics and that those who are disease- or metastases-
free are less likely to attend clinics, the latter group will be cen-
sored earlier, and will stop contributing information to the study.
Thus the censoring is potentially dependent on the likelihood of
disease progression (i.e., related to the outcome). This is another
source of potential bias, as the rate of censoring does not leave a
representative sample of those at risk. Therefore Cochrane Breast
Cancer Group statisticians advised us that the censoring is likely to
be informative and the assumption of non-informative censoring
required for the KM method is likely to be violated.
(3) Heterogeneity of interventions
For the surgery alone versus primary endocrine therapy compar-
ison, there was heterogeneity between trials in terms of interven-
tions. One study (St Georges) included larger (T3 and T4) tu-
mours in the surgical arm, which would result in an increased local
recurrence rate. The other two trials included only participants
with T1 - T2 (Nottingham 1) and T1 - T3a (EORTC 10851) tu-
mours respectively. The St Georges study treated 64 women with
wide local excision and 36 with mastectomy; in the Nottingham
1 and EORTC 10851 trials all women were treated with mastec-
tomy. It is arguable, therefore, that St Georges is different enough
in terms of its populations and interventions to make statistical
synthesis with the other two studies inappropriate. Nevertheless,
both the populations and interventions of all included studies are
in conformity with the inclusion criteria for this review.
(4) Heterogeneity of outcome assessments
For the surgery-alone versus primary endocrine therapy compar-
ison, there was a difference between the deﬁnitions of distant
metastasis-free interval between the two trials: in EORTC 10851
they have counted some distant events which occurred after local
events; in St Georges they have only counted ﬁrst events. This
made it inappropriate to combine the outcomes from the two
trials. For the surgery plus endocrine therapy versus primary en-
docrine therapy comparison, evidence of heterogeneity between
trials was identiﬁed for local disease control; funnel plots were not
practical, with only two included trials, and the reasons must re-
main speculative. It is possible that here too there is a difference
between each trial’s outcome deﬁnitions in terms of whether only
ﬁrst events were counted.
Potential biases in the review process
An overview of the bias assessment is summarised in Figure 1.
Agreements and disagreements with other
studies or reviews
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This is the only published meta-analysis of randomised controlled
trials comparing surgery (with or without adjuvant endocrine ther-
apy) with primary endocrine therapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Primary endocrine therapy should only be offered to women with
ER-positive tumours who are unﬁt or borderline-ﬁt for surgery,
or who refuse it. In a cohort of women with reduced life ex-
pectancy, due to signiﬁcant co-morbid disease, and ER-positive
tumours, primary endocrine therapy may be an appropriate treat-
ment choice.
Implications for research
Trials are needed to evaluate the clinical effectiveness of aromatase
inhibitors as primary therapy for an inﬁrm older population with
ER-positive tumours. The Bridging the AgeGap study - a national
UK cohort study - may provide more clinically relevant answers
to this question.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
CRC
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery plus tamoxifen (40 mg/d) versus tamoxifen alone
Outcomes Survival - overall; Disease-free survival; Local disease control; Distant metastasis-free
survival; Quality of life
Notes Comparability between groups at the baseline: stated as “good”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Central randomisation.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis -
16 protocol violators (full explanations) analysed as ran-
domised (intention-to-treat)
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes.
EORTC 10851
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery versus tamoxifen (20 mg/d)
Outcomes Survival - overall; Disease-free survival; Local disease control; Distant metastasis free
survival
Notes Comparability between groups at the baseline: stated as “well-balanced”
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EORTC 10851 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated (but stated that it was randomised).
Allocation concealment (selection bias) Low risk Central randomisation.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis:
analysis based on intention-to-treat. 13 found ineligible
after randomisation and excluded from analysis. 1 par-
ticipant allocated tamoxifen opted for surgery
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes.
GRETA
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery plus tamoxifen (20 mg/d) versus tamoxifen alone
Outcomes Survival - overall; Disease-free survival; Local disease control; Distant metastasis free
survival
Notes Comparability between groups at the baseline: good
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number
Allocation concealment (selection bias) Low risk Central randomisation.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
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GRETA (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis:
intention-to-treat analysis
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes
Naples
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery plus tamoxifen (20 mg/d) versus tamoxifen alone
Outcomes Survival - overall; Disease-free survival
Notes No data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in results presented.
Selective reporting (reporting bias) Unclear risk Adequate outcomes reported on but insufﬁcient data pre-
sented for meta-analysis
Nottingham 1
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery versus tamoxifen (40 mg/d)
Outcomes Survival - overall; Disease-free survival; Local disease control; Distant metastasis-free
survival
25Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus) (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nottingham 1 (Continued)
Notes Comparability between groups at the baseline: appears similar by age, tumour volume
and tumour site. Little else speciﬁed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random card allocation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis:
analysis based on intention-to-treat. 2 incorrect randomi-
sations in each group. 122/135 followed up. Other 13
participants assessed by GP at time of analysis as too frail
to attend clinic
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes
Nottingham 2
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery plus tamoxifen versus tamoxifen (20 mg/d)
Outcomes Survival - overall; Disease-free survival
Notes Comparability between groups at the baseline: stated as “similarly matched for age” (no
other characteristics reported)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Nottingham 2 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis:
analysed as randomised (intention-to-treat)
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes
St Georges
Methods Randomised controlled trial
Participants Women (aged 70+) with operable breast cancer
Interventions Surgery versus tamoxifen (20 mg/d)
Outcomes Survival - overall; Disease-free survival; Local disease control; Distant metastasis free
survival
Notes Comparability between groups at the baseline: More T4 tumours in primary endocrine
therapy group (n=14/100 versus n=7/100 in the surgery group) but, with small numbers
in each arm, this may not be signiﬁcant. Ages were similar. No other characteristics were
reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of these studies was not possible due to inter-
ventions used, therefore this has not been assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Inclusion of all randomised participants in the analysis:
no errors or exclusions were reported
Selective reporting (reporting bias) Low risk Sufﬁcient data reported on all relevant outcomes
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D A T A A N D A N A L Y S E S
Comparison 1. Surgery versus primary endocrine therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival - overall 3 495 Hazard Ratio (95% CI) 0.98 [0.81, 1.20]
Comparison 2. Surgery plus endocrine therapy versus primary endocrine therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival - overall 3 1076 Hazard Ratio (95% CI) 0.86 [0.73, 1.00]
2 Local disease control 2 929 Hazard Ratio (95% CI) 0.28 [0.23, 0.35]
A D D I T I O N A L T A B L E S
Table 1. Source data for comparisons
Comparison Outcome Trial Follow-up Summary statis-
tics
Observed events
(n)
Subsection of
Parmar 1998
Surgery ver-
sus primary en-
docrine therapy
Survival - overall EORTC 10851 Approx-
imately 10 years.
Surgery: median
11.7 years (95%
CI: 11.2 to 12.
8; range: 0 - 14.
3). Primary en-
docrine therapy:
10.2 years (95%
CI: 10.3 to 11.2;
range: 0 - 14.9)
Fentiman 2003:
Kaplan-Meier
Curves; Fmin
and Fmax stated
in paper.
Fentiman 2003;
Table 2, “Total
deceased”.
Subsection 5
Surgery ver-
sus primary en-
docrine therapy
Survival - overall Nottingham 1 Median 73
and 74 months.
Maximum fol-
low-up 20 years
Chakrabarti
2011: Kaplan-
Meier Curves.
Fmin taken as
ﬁrst event; Fmax
stated in paper
Chakrabarti
2011. Table 1.
Subsection 5
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Table 1. Source data for comparisons (Continued)
Surgery ver-
sus primary en-
docrine therapy
Survival - overall St Georges Range: 0 - 28
years
Gazet 2011: Ka-
plan-Meier
Curves
Gazet and Sut-
cliffe 2011:Table
1
Subsection 5
Surgery ver-
sus primary en-
docrine therapy
Progression-free
survival
EORTC 10851 Approx-
imately 10 years.
Surgery: median
11.7 years (95%
CI: 11.2 to 12.
8; range: 0 - 14.
3). Primary en-
docrine therapy:
10.2 years (95%
CI: 10.3 to 11.2;
range: 0 - 14.9)
Fentiman 2003,
Table 3 (p 314):
number of events
and number ran-
domised for each
arm; P value
Fentiman 2003;
Table 3, ’Pro-
gression-free sur-
vival: number of
events’
Subsection 5
Surgery ver-
sus primary en-
docrine therapy
Local disease
control
EORTC 10851 Approx-
imately 10 years.
Surgery: median
11.7 years (95%
CI: 11.2 to 12.
8; range: 0 - 14.
3). Primary en-
docrine therapy:
10.2 years (95%
CI: 10.3 to 11.2;
range: 0 - 14.9)
Fentiman 2003:
Kaplan-Meier
Curves; Fmin
and Fmax stated
in paper
Fentiman 2003;
Table 3, ’Time
to loco-regional
progression’
Subsection 5
Surgery ver-
sus primary en-
docrine therapy
Local disease
control
Nottingham 1 Me-
dian 145 months
(range: 116 - 180
months)
Kenny 1998:
Life tables
Kenny 1998;
Figure 1, ’Local
control by pri-
mary treatment
Subsection 5
Surgery ver-
sus primary en-
docrine therapy
Local disease
control
St Georges Median 6 years
(range 3 - 11
years)
Mar-
tin Bland per-
sonal communi-
cation:
Anonymised
IPD from which
hazard ratios and
95% conﬁdence
intervalswere de-
rived
Gazet 1994; p
208
Subsection 4
Surgery ver-
sus primary en-
docrine therapy
Distant metasta-
sis-free survival
EORTC 10851 Approx-
imately 10 years.
Surgery: median
11.7 years (95%
Fentiman 2003:
Kaplan-Meier
Curves; Fmin
and Fmax stated
Fentiman 2003;
Table
2, added ﬁgures
for, ’Distant [re-
Subsection 5
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Table 1. Source data for comparisons (Continued)
CI: 11.2 - 12.
8; range: 0 - 14.
3). Primary en-
docrine therapy:
10.2 years (95%
CI: 10.3 to 11.2;
range: 0 - 14.9)
in paper lapse]“ and ”Lo-
cal and distant’
Surgery ver-
sus primary en-
docrine therapy
Distant metasta-
sis-free survival
St Georges Median 6 years
(range 3 - 11
years)
Mar-
tin Bland per-
sonal communi-
cation:
Anonymised
IPD from which
hazard ratios and
95% conﬁdence
intervalswere de-
rived (
Bland 2005 [pers
comm])
Gazet 1994; p
210
Subsection 4
Surgery plus en-
docrine therapy
ver-
sus primary en-
docrine therapy
Survival - overall CRC Median 12.7
years
Fennessey 2004
p 702: Hazard
ratios and 95%
conﬁdence inter-
vals
Fennessey 2004,
Table 4
Subsection 4
Surgery plus en-
docrine therapy
ver-
sus primary en-
docrine therapy
Survival - overall GRETA 80 months. Mustacchi per-
sonal commu-
nication: Hazard
ratios and 95%
conﬁdence inter-
vals
(Mustacchi 2005
[pers comm])
Mustacchi 2003;
Table 4.
Subsection 4
Surgery plus en-
docrine therapy
ver-
sus primary en-
docrine therapy
Survival - overall Nottingham 2 60 months. Willsher 1997:
Life Table re-
porting grouped
data; Fmin as-
sumed the same
as Nottingham
1 (same trialists,
same protocol);
Fmax 60 months
- from life table
Used ’effec-
tive number of
deaths in t’
Subsection 5
Surgery plus en-
docrine therapy
Progression-free
survival
GRETA 80 months. Mustacchi 2003;
observed events
Mustacchi 2003;
Table 4; ’Total
Subsection 5
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Table 1. Source data for comparisons (Continued)
ver-
sus primary en-
docrine therapy
for research and
control; num-
bers randomised
to research and
control; P value
events.
Surgery plus en-
docrine therapy
ver-
sus primary en-
docrine therapy
Local disease
control
GRETA 80 months. Mustacchi 2003;
Figure
1: Kaplan-Meier
Curve
Mustacchi 2003;
Table 4; ’First lo-
cal progression’
Subsection 5
Surgery plus en-
docrine therapy
ver-
sus primary en-
docrine therapy
Local disease
control
CRC Median 12.7
years.
Hazard Ratios
from Fennessey
2004 p 701;
Fmin from Table
1, Fmax from last
entry on curve.
Fennessey 2004,
Table 2, ’Local’ +
’Axillary’
Subsection 4
WH A T ’ S N E W
Last assessed as up-to-date: 27 March 2013.
Date Event Description
19 May 2014 Review declared as stable As clinical practice and consumer preference have started to change in recent years, it
is unlikely that new trials will compare surgery versus primary endocrine therapy. The
authors therefore do not expect to update this review in the future
H I S T O R Y
Protocol ﬁrst published: Issue 3, 2002
Review ﬁrst published: Issue 1, 2006
Date Event Description
27 March 2013 New search has been performed Performed search for new studies on 27 March 2013.
No new studies included. Data has been updated
for two already-included studies (Nottingham 1; St
Georges)
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(Continued)
27 March 2013 New citation required but conclusions have not
changed
This review update includes an accumulation of
changes. These are: changes in authorship, the inclu-
sion of updated data from two studies, full risk of bias
tables and ’Summary of ﬁndings’ tables
9 May 2008 Amended Converted to new review format.
13 November 2007 New search has been performed Review updated - no new citation. new search, no new
trials to add
16 November 2005 New search has been performed First review publication
27 May 2003 Amended Protocol ﬁrst published
C O N T R I B U T I O N S O F A U T H O R S
For the 2013 review update:
JM screened the search results
JM organised the retrieval of papers
JM and LW screened retrieved papers against inclusion criteria
JM entered data into Review Manager 5
JM, LW, KC and MR analysed and interpreted the data
JM, LW, KC and MR wrote and edited the update
D E C L A R A T I O N S O F I N T E R E S T
This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants
for Applied Research Programme (Grant Reference Number RP-PG-1209-10071). The views expressed are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health.
S O U R C E S O F S U P P O R T
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Internal sources
• North Trent Cancer Research Network, UK.
External sources
• No sources of support supplied
N O T E S
1. Types of outcome measures - We have made an amendment to the second primary outcome to make clear that the event numbers
for the outcome progression-free survival include both cancer progression and death events from any cause.
The protocol originally read:
“disease-free survival (interval between start of treatment and need for second line treatment/palliative treatment/recurrence)”
It now reads:
“progression-free survival (interval between start of treatment and need for second line treatment/palliative treatment/ recurrence/death
from any cause)”
This has been modiﬁed to allay confusion between trials which record disease-free survival (which counts death as an event) and disease-
free interval (which does not). The outcome we had originally deﬁned (the text in brackets) was ’disease-free interval’. We had created
the potential for confusion by then calling the outcome disease-free survival as they are different outcomes.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antineoplastic Agents, Hormonal [∗therapeutic use]; Breast Neoplasms [∗drug therapy; ∗surgery]; Combined Modality Therapy;
Randomized Controlled Trials as Topic; Tamoxifen [∗therapeutic use]
MeSH check words
Aged; Aged, 80 and over; Female; Humans
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